Bain Capital Private Equity
VC Fund
London, United Kingdom
Bain Capital Private Equity is a private equity firm that focuses on a value-added investment approach. Their globally integrated teams leverage deep vertical expertise and partner with management teams around the world to accelerate growth.
- Total investments:
- 22
- Last investment:
- Lead investor:
- 45%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Bain Capital Private Equity invests in
Stages Bain Capital Private Equity invests in
Countries Bain Capital Private Equity invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
2 more contacts available
Round size
- Series A
- $17M–$108M
- Private Equity
- $108M–$550M
- Post-IPO Equity
- $800M–$855M
Investment Focus
Industry
- Health Care 8 (36%)
- Biotechnology 5 (23%)
- Manufacturing 4 (18%)
- Pharmaceutical 4 (18%)
- Medical 3 (14%)
Stage
- Private Equity 11 (50%)
- Post-IPO Equity 3 (14%)
- Series A 2 (9%)
- Series B 2 (9%)
- Series C 1 (5%)
Country
- United States 12 (55%)
- China 2 (9%)
- Japan 2 (9%)
- Italy 1 (5%)
- Germany 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Adam Koppel
Managing Director
|
Managing Director | Total investments: 10 | Find email | |
Chris Gordon
Managing Director
|
Managing Director | Total investments: 3 | Find email | |
John Connaughton
Global Head
|
Global Head | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Kailera Therapeutics
|
Kailera Therapeutics is a clinical-stage biotechnology company that provides revolutionary therapies for treating obesity and related diseases. | $600M / Series B / Oct 14, 2025 | |
Cardurion Pharmaceuticals
|
Cardurion Pharmaceuticals is a Boston-based biotechnology company focused on developing novel therapeutics for the treatment of heart failure and other cardiovascular diseases. The company is advancing groundbreaking clinical programs targeting PDE9 and CaMKII inhibition, leveraging its expertise in cardiovascular signaling pathways to addressunmet patient needs. | $260M / Series B / Jul 16, 2024 | |
Proterial
|
Proterial is a manufacturing and trading company providing automobile castings, piping equipment, magnetic materials, and parts. | Private Equity / Jan 01, 2023 | |
Arxada
|
Arxada is a chemical solutions manufacturer. They provide combineering, microbial control solutions, specialty chemical services, hygiene, home, personal care, paints, coatings, material protection, wood protection, crop protection, CDMO, composite materials, performance intermediates, chemicals, and white biotech. The company also provides customdevelopment, manufacturing organization, and performance intermediates and chemicals. | Private Equity / Jan 01, 2023 | |
Aveanna Healthcare
|
Aveanna Healthcare brings together two of the largest providers of pediatric care in the nation – Epic Health Services and PSA Healthcare. As Aveanna, we have joined together to revolutionize the way pediatric healthcare is delivered, one patient at a time. Today, the Aveanna Healthcare family of companies cares for medically fragile patients in 23states through our rapidly growing network of more than 200 branch offices. As a result of overwhelming demand for the quality of care we consistently give, Aveanna has also been providing more and more adult home care services. | Post-IPO Equity / Jan 01, 2023 | |
Nexi Group
|
Nexi Group is a finance firm that provides e-commerce, digital payment, investment in technology and innovation, and multi-channel services. | Private Equity / Jan 01, 2023 | |
Surgery Partners
|
Surgery Partners acquires, develops, and manages free-standing ambulatory surgical centers (ASCs) in partnership with leading physicians. The company owns and operates twelve ASCs. As one of the largest ASC operators in the Southeast, Surgery Partners is dedicated to clinical excellence in outpatient surgery services and provides its centers withexperienced and efficient operations leadership, development expertise, and practice partnership. | $800M / Post-IPO Equity / Nov 21, 2022 | |
CitiusTech
|
CitiusTech - A unicorn with $200M+ revenue is specialist provider of healthcare technology services and solutions to healthcare technology companies, providers, payers and life sciences organizations. With over 4,000 professionals worldwide, CitiusTech enables healthcare organizations to drive clinical value chain excellence, across integration& interoperability, data management (EDW, Big Data), performance management (BI / analytics), predictive analytics & data science, and digital engagement (mobile, IoT).CitiusTech helps customers accelerate innovation in healthcare through specialized solutions, healthcare technology platforms, proficiencies and accelerators. Armed with cutting-edge technology & expertise, world-class service quality and a global resource base, CitiusTech consistently delivers best-in-class solutions along with an unmatched cost advantage to healthcare organizations worldwide. CitiusTech recently acquired FluidEdge Consulting (FluidEdge), a national healthcare management consulting company headquartered in Philadelphia, PA. FluidEdge has been ranked in the Inc 5000 as one of the fastest growing private companies in the United States. FluidEdge is now a wholly owned subsidiary of CitiusTech. CitiusTech has been recognized as a great place to work by the Great Place to Work Institute® for eight consecutive years (2012 to 2019). CitiusTech has also been listed in the 2018 Healthcare Informatics (HCI) 100, placing it among the top 100 healthcare technology companies in the US, for the third consecutive year. CitiusTech has also been closely associated with key industry organizations, such as HIMSS, HL7, CHIME Foundation, AHIP and ACHP. | Private Equity / Oct 20, 2022 | |
Virgin Voyages
|
Virgin Voyages is a lifestyle travel brand offering cruise vacations across different destinations. Its services offer luxury cruise ship travel services, suites, and entertainment services to provide its customers with adventurous places and experiences. | $550M / Private Equity / Aug 16, 2022 | |
EcoCeres
|
EcoCeres is an innovative biomass utilization company with strong R&D capability and excellent ESG performance. EcoCeres focuses on the utilization of bio-grease and agricultural waste. EcoCeres creates decarbonization solutions to help the world achieve carbon neutrality. | $108M / Private Equity / Feb 24, 2022 | |
| See all 22 investments → | |||
Co-Investors
Bain Capital
3 deals together
Bain Capital Life Sciences
3 deals together
CPP Investments
2 deals together
Google Ventures
2 deals together
Invus
2 deals together
Joy Capital
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Bain Capital Private Equity invest in?
Bain Capital Private Equity invests primarily in Health Care, Biotechnology and Manufacturing startups, most often at Private Equity and Post-IPO Equity stage. Most of the 22 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Bain Capital Private Equity's check size?
Bain Capital Private Equity typically joins rounds of $17M–$108M at Series A, $108M–$550M at Private Equity and $800M–$855M at Post-IPO Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Bain Capital Private Equity participates in.
How do I contact Bain Capital Private Equity?
Public channels for Bain Capital Private Equity include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Bain Capital Private Equity?
The team at Bain Capital Private Equity includes Adam Koppel (Managing Director), Chris Gordon (Managing Director) and John Connaughton (Global Head). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
